Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Sherrica Tai"'
Autor:
Lirit N. Franks, Peter A. Crooks, William E. Fantegrossi, Christian V. Cabanlong, Benjamin M. Ford, Narsimha Reddy Penthala, Paul L. Prather, Sherrica Tai
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 369:259-269
Most cannabinoid 1 receptor (CB1R) agonists will signal through both G protein-dependent and -independent pathways in an unbiased manner. Recruitment of β-arrestin 2 desensitizes and internalizes receptors, producing tolerance that limits therapeuti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3dbc0fbee5f3ae3d7f8969e982eb6931
https://doi.org/10.1124/jpet.118.252965
https://doi.org/10.1124/jpet.118.252965
Publikováno v:
Trends in Pharmacological Sciences. 38:257-276
In the early 2000s in Europe and shortly thereafter in the USA, it was reported that ‘legal' forms of marijuana were being sold under the name K2 and/or Spice. Active ingredients in K2/Spice products were determined to be synthetic cannabinoids (SC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e82fdaf2cd6e0e1af952dc1c77307ba
https://doi.org/10.1016/j.tips.2016.12.003
https://doi.org/10.1016/j.tips.2016.12.003
Autor:
Sherrica Tai, Minghua Li, Kylie B. McPherson, Susan L. Ingram, Emily R. Leff, Claire Meurice, John R. Traynor
Regulators of G-protein signaling (RGS) proteins negatively modulate presynaptic μ-opioid receptor inhibition of GABA release in the ventrolateral periaqueductal gray (vlPAG). Paradoxically, we find that G-protein-coupled receptor (GPCR) activation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4630f1bb3655faf0b12cb8aca112e01
https://europepmc.org/articles/PMC6181307/
https://europepmc.org/articles/PMC6181307/
Autor:
Benjamin M, Ford, Christian V, Cabanlong, Sherrica, Tai, Lirit N, Franks, Narsimha R, Penthala, Peter A, Crooks, Paul L, Prather, William E, Fantegrossi
Publikováno v:
J Pharmacol Exp Ther
Most cannabinoid 1 receptor (CB(1)R) agonists will signal through both G protein–dependent and –independent pathways in an unbiased manner. Recruitment of β-arrestin 2 desensitizes and internalizes receptors, producing tolerance that limits ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::592e2a61cb874de6216027bb784b752e
https://pubmed.ncbi.nlm.nih.gov/30833484
https://pubmed.ncbi.nlm.nih.gov/30833484
Publikováno v:
The FASEB Journal. 32
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c324b0e696a87bf3d6a772c34e37f28
https://doi.org/10.1096/fasebj.2018.32.1_supplement.825.4
https://doi.org/10.1096/fasebj.2018.32.1_supplement.825.4
Autor:
Tamara Vasiljevik, Sherrica Tai, Sarah Eddington, Thomas E. Prisinzano, Catheryn D. Wilson, Alexander M. Sherwood, William E. Fantegrossi
Publikováno v:
Drug and alcohol dependence. 192
Background Cannabinoids may be useful in the treatment of CNS disorders including drug abuse and addiction, where both CB1R antagonists / inverse agonists and CB2R agonists have shown preclinical efficacy. TV-5-249 and TV-6-41, two novel aminoalkylin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b2d7a682fa2f8a087fc3e6d0b755a88
https://pubmed.ncbi.nlm.nih.gov/30300803
https://pubmed.ncbi.nlm.nih.gov/30300803
Autor:
Tamara Vasiljevik, Lirit N. Franks, Sherrica Tai, William E. Fantegrossi, William S. Hyatt, Paul L. Prather, Lisa K. Brents, C. Gu
Publikováno v:
Pharmacological Research. 102:22-32
These studies probed the relationship between intrinsic efficacy and tolerance/cross-tolerance between ∆(9)-THC and synthetic cannabinoid drugs of abuse (SCBs) by examining in vivo effects and cellular changes concomitant with their repeated admini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a0fa4055eb9f023cdbedb60579c6732
https://doi.org/10.1016/j.phrs.2015.09.006
https://doi.org/10.1016/j.phrs.2015.09.006
Autor:
Spyros P. Nikas, Alexandros Makriyannis, Torbjörn U. C. Järbe, Sherrica Tai, Kiran Vemuri, Vidyanand G. Shukla
Publikováno v:
Psychopharmacology. 232:2751-2761
Previous reports shows rimonabant’s inverse properties may be a limiting factor for treating cannabinoid dependence. To overcome this limitation, neutral antagonists were developed, to address mechanisms by which an inverse agonist and neutral anta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2416d6cc8945ffe4600af37f503b5b93
https://doi.org/10.1007/s00213-015-3907-0
https://doi.org/10.1007/s00213-015-3907-0
Autor:
Paul L. Prather, Benjamin M. Ford, Peter A. Crooks, William E. Fantegrossi, Narsimha Reddy Penthala, Christian V. Cabanlong, Sherrica Tai, Michael D. Berquist, Edward L. Stahl, Catheryn D. Wilson, Lirit N. Franks
The human cannabinoid subtype 1 receptor (hCB1R) is highly expressed in the CNS and serves as a therapeutic target for endogenous ligands as well as plant-derived and synthetic cannabinoids. Unfortunately, acute use of hCB1R agonists produces unwante
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d4aa750a74aa1b772224461d2929c56
https://europepmc.org/articles/PMC5849406/
https://europepmc.org/articles/PMC5849406/